
Journal of Diagnostics Concepts & Practice››2023,Vol. 22››Issue (06): 541-549.doi:10.16150/j.1671-2870.2023.06.005
• Academic trend at home and abroad •Previous ArticlesNext Articles
Received:2023-04-17Online:2023-12-25Published:2024-03-18Contact:JIANG Xiaofei E-mail:jiangxi2154@aliyun.comTable 1
Global number of deaths and age-standardised mortality rate per 100 000 population by bacterial pathogen and infectious syndrome, 2019
| 项目 | 下呼吸道感染和胸部所有相关感染 | 血液感染 | 腹膜和腹腔内感染 |
|---|---|---|---|
| 金黄色葡萄球菌 | |||
| 死亡人数(万人) | 53.2 (44.0~64.8) | 29.9 (16.6~48.5) | 16.9 (10.5~25.3) |
| 年龄标准化死亡率(/10万) | 7.3 (6.0~8.8) | 3.9 (2.1~6.3) | 2.1 (1.3~3.2) |
| 大肠埃希菌 | |||
| 死亡人数(万人) | 18.1 (14.2~23.0) | 24.2 (13.3~39.8) | 29.0 (18.8~42.3) |
| 年龄标准化死亡率(/10万) | 2.6 (2.0~3.2) | 3.2 (1.7~5.2) | 3.7 (2.4~5.4) |
| 肺炎链球菌 | |||
| 死亡人数(万人) | 65.3 (55.3~77.7) | 12.5 (7.3~19.9) | - |
| 年龄标准化死亡率(/10万) | 9.1(7.7~10.8) | 1.6 (1.0~2.6) | - |
| 肺炎克雷伯菌 | |||
| 死亡人数(万人) | 27.6 (22.0~34.3) | 26.5 (15.7~41.6) | 15.8 (10.3~23.4) |
| 年龄标准化死亡率(/10万) | 3.8 (3.1~4.8) | 3.5 (2.1~5.5) | 2.0 (1.3~2.9) |
| 铜绿假单胞菌 | |||
| 死亡人数(万人) | 23.3 (18.1~30.2) | 16.3 (9.5~25.5) | 10.3 (6.6~15.1) |
| 年龄标准化死亡率(/10万) | 3.2 (2.5~4.1) | 2.1 (1.2~3.3) | 1.3 (0.8~1.9) |
| 鲍曼不动杆菌 | |||
| 死亡人数(万人) | 16.6 (9.2~26.7) | 24.7 (13.8~40.5) | - |
| 年龄标准化死亡率(/10万) | 2.2 (1.2~3.5) | 3.2 (1.8~5.2) | - |
| B组链球菌 | |||
| 死亡人数(万人) | 18.2 (14.0~23.4) | 7.6 (4.4~11.9) | - |
| 年龄标准化死亡率(/10万) | 2.6 (2.0~3.4) | 1.0 (0.6~1.6) | - |
| 脑膜炎奈瑟氏菌 | |||
| 死亡人数(万人) | - | 11.0 (6.8~16.8) | - |
| 年龄标准化死亡率(/10万) | - | 1.5 (1.0~2.3) | - |
| 粪肠球菌 | |||
| 死亡人数(万人) | - | 7.5 (4.4~11.8) | 11.3 (6.0~18.6) |
| 年龄标准化死亡率(/10万) | - | 1.0 (0.6~1.6) | 1.4 (0.7~2.3) |
| 屎肠球菌 | |||
| 死亡人数(万人) | - | 7.8 (4.4~12.6) | 11.8 (7.2~18.5) |
| 年龄标准化死亡率(/10万) | - | 1.0 (0.6~1.6) | 1.5 (0.9~2.3) |
Table 2
YLLs by pathogen and infectious syndrome in 2019
| 病原体 | 下呼吸道感染和胸部所有相关感染 | 血液感染 | 腹膜和腹腔内感染 |
|---|---|---|---|
| 金黄色葡萄球菌 | 1 760 (1 440~2 160) | 847 (509~1290) | 491 (290~749) |
| 大肠埃希菌 | 970 (720~1 280) | 607 (363~927) | 739 (459~1 110) |
| 肺炎链球菌 | 3 250 (2 710~3 950) | 496 (307~741) | - |
| 肺炎克雷伯菌 | 1 350 (1 060~1 710) | 1 070 (684~1 550) | 386 (242~582) |
| 铜绿假单胞菌 | 914 (714~1 160) | 597 (377~891) | 262 (159~397) |
Table 3
Deaths by pathogen and the top 3 leading infectious syndromes by GBD super-region in 2019
| 地区及感染类型 | 病原体 | ||||
|---|---|---|---|---|---|
| 金黄色葡萄球菌 | 大肠埃希菌 | 肺炎链球菌 | 肺炎克雷伯菌 | 铜绿假单胞菌 | |
| 东南亚、东亚和大洋洲 | |||||
| 1类 | 9.45(5.25~15.60) | 4.19(2.28~6.92) | 2.86(1.58~4.65) | 5.31(2.97~8.74) | 4.43(2.44~7.24) |
| 2类 | 8.09(6.25~10.50) | 2.46(1.88~3.24) | 12.00(9.58~15.00) | 3.89(2.92~5.14) | 4.24(2.94~6.03) |
| 3类 | 4.00(2.40~6.15) | 6.90(4.26~10.70) | - | 3.64(2.27~5.54) | 2.52(1.54~3.87) |
| 中欧、东欧及中亚 | |||||
| 1类 | 2.39(1.27~4.07) | 3.83(2.01~6.57) | 1.13(0.60~1.91) | 1.75(0.94~2.97) | 0.84(0.45~1.44) |
| 2类 | 2.63(2.08~3.42) | 0.56(0.43~0.74) | 2.59(2.18~3.15) | 0.93(0.71~1.25) | 1.15(0.81~1.65) |
| 3类 | 1.52(0.94~2.24) | 2.57(1.65~3.73) | - | 1.27(0.82~1.85) | 0.98(0.63~1.44) |
| 高收入超级地区 | |||||
| 1类 | 9.18(4.89~15.40) | 7.62(4.01~13.00) | 1.88(1.00~3.15) | 3.41(1.83~5.72) | 2.12(1.14~3.56) |
| 2类 | 13.70(11.40~16.30) | 1.71(1.40~2.08) | 7.08(6.01~8.23) | 2.80(2.27~3.44) | 4.31(3.35~5.60) |
| 3类 | 3.16(2.05~4.62) | 6.16(4.00~9.00) | - | 2.81(1.85~4.11) | 2.52(1.65~3.66) |
| 拉丁美洲及加勒比海 | |||||
| 1类 | 2.06(1.14~3.38) | 1.74(0.94~2.90) | 0.93(0.53~1.48) | 2.05(1.17~3.29) | 1.27(0.72~2.04) |
| 2类 | 5.06(4.15~6.21) | 1.15(0.91~1.46) | 4.20(3.53~5.02) | 1.93(1.51~2.45) | 1.97(1.47~2.64) |
| 3类 | 1.57(1.01~2.30) | 2.70(1.84~3.84) | - | 1.48(0.98~2.12) | 0.94(0.62~1.36) |
| 北非和中东 | |||||
| 1类 | 1.56(0.85~2.54) | 1.14(0.62~1.87) | 0.73(0.41~1.19) | 1.55(0.88~2.45) | 0.98(0.54~1.56) |
| 2类 | 2.66(2.09~3.40) | 0.90(0.67~1.20) | 3.21(2.58~3.95) | 1.37(1.04~1.79) | 1.23(0.90~1.68) |
| 3类 | 1.00(0.59~1.57) | 1.71(1.05~2.63) | - | 0.96(0.59~1.45) | 0.59(0.36~0.92) |
| 南亚 | |||||
| 1类 | 3.20(1.80~5.22) | 3.34(1.81~5.48) | 2.69(1.51~4.28) | 6.48(3.72~10.30) | 3.89(2.18~6.32) |
| 2类 | 9.34(7.28~12.00) | 4.84(3.63~6.42) | 16.00(13.10~19.70) | 7.06(5.37~9.07) | 5.03(3.79~6.61) |
| 3类 | 3.60(2.08~5.69) | 5.80(3.63~8.45) | - | 3.60(2.28~5.51) | 1.79(1.09~2.86) |
| 撒哈拉以南非洲 | |||||
| 1类 | 2.04(1.37~2.97) | 2.36(1.51~3.50) | 2.32(1.53~3.40) | 5.93(3.95~8.52) | 2.74(1.81~3.97) |
| 2类 | 11.70(9.55~14.30) | 6.46(4.89~8.47) | 20.30(16.60~24.80) | 9.57(7.62~11.90) | 5.36(4.29~6.66) |
| 3类 | 2.07(1.19~3.27) | 3.16(2.02~4.60) | - | 2.03(1.30~3.12) | 0.93(0.54~1.48) |
| [1] | UN. Sustainable Development Goals[R/OL]. 2022-01-27[2023-04-17]. https://www.un.org/sustainabledevelopment/sustainable-development-goals/. |
| [2] | UN. Millennium Development Goals[R/OL]. 2022-01-27[2023-04-17]. https://www.un.org/millenniumgoals/. |
| [3] | GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J].Lancet,2020,396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9pmid:33069326 |
| [4] | Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis[J].Lancet,2022,399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0pmid:35065702 |
| [5] | WHO, UNICEF. Ending preventable child deaths from pneumonia and diarrhoea by 2025:the integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD).2013[R/OL]. 2021-11-08[2023-04-17]. https://apps.who.int/iris/bitstream/handle/10665/79207/WHO_FWC_MCA_13_01_eng.pdf?sequence=1. |
| [6] | WHO. Sepsis. Geneva: World Health Organization[R/OL]. 2021-11-08[2023-04-17]. https://www.who.int/news-room/fact-sheets/detail/sepsis |
| [7] | WHO. Global report on the epidemiology and burden of sepsis:current evidence, identifying gaps and future directions. Geneva: World Health Organization, 2020[R/OL]. https://apps.who.int/iris/handle/10665/334216 |
| [8] | SARTELLI M, CHICHOM-MEFIRE A, LABRICCIOSA F M, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections[J].World J Emerg Surg,2017,12:29. doi:10.1186/s13017-017-0141-6pmid:28702076 |
| [9] | ALKIRE B C, RAYKAR N P, SHRIME M G, et al. Global access to surgical care: a modelling study[J].Lancet Glob Health,2015,3(6):e316-e23. doi:10.1016/S2214-109X(15)70115-4URL |
| [10] | HOLMER H, LANTZ A, KUNJUMEN T, et al. Global distribution of surgeons, anaesthesiologists, and obstetricians[J].Lancet Glob Health,2015,3(Suppl 2):S9-S11. |
| [11] | WHO. Immunization agenda 2030: a global strategy to leave no one behind[R/OL]. Geneva: World Health Organization.2020-04[2023-04-17]. https://www.who.int/publications/m/item/immunization-agenda-2030-aglobal-stra-tegy-to-leave-no-one-behind. |
| [12] | ALLEGRANZI B, BISCHOFF P, DE JONGE S, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective[J].Lancet Infect Dis,2016,16(12): e276-e287. doi:10.1016/S1473-3099(16)30398-Xpmid:27816413 |
| [13] | TACCONELLI E. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics[R/OL].World Health Organization.2017[2023-04-17]. https://policycommons.net/artifacts/1818147/global-priority-list-of-antibiotic-resistant-bacteriato-guide-research-discovery-and-development/2555608/. |
| [14] | WHO. Antimicrobial resistance: global report on surveillance[R/OL]. Geneva: World Health Organization.2014[2023-04-17]. https://apps.who.int/iris/handle/10665/112642. |
| [15] | O'BRIEN K L, WOLFSON L J, WATT J P, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates[J].Lancet,2009,374(9693):893-902. doi:10.1016/S0140-6736(09)61204-6pmid:19748398 |
| [16] | US Centers for Disease Control and Prevention. GBS Surveillance Report 2019. Centers for Disease Control and Prevention, 2019[R/OL]. 2021-12-08[2023-04-17]. https://www.cdc.gov/abcs/downloads/GBS_Surveillance_Report_2019.pdf. |
| [17] | GBD2019Tuberculosis Collaborators. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019[J].Lancet Infect Dis,2022,22(2):222-241. doi:10.1016/S1473-3099(21)00449-7URL |
| [18] | WHO. WHO Model List of Essential Medicines - 22nd list, 2021[R/OL]. Geneva: World Health Organization.2021-08-30[2023-04-17]. https://www.who.int/publications-detail-redirect/WHO-MHP-HPS-EML-2021.02. |
| [19] | O'BRIEN K L, WOLFSON L J, WATT J P, et al. Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis[J].PLoS Med,2021,18(9):e1003787. doi:10.1371/journal.pmed.1003787URL |
| [20] | DO N T T, VU H T L, NGUYEN C T K, et al. Community-based antibiotic access and use in six low-income and middle-income countries: a mixed-method approach[J].Lancet Glob Health,2021,9(5):e610-e619. |
| [21] | WHO. WHO antibiotic categorization[R/OL]. Geneva: World Health Organization.[2023-04-17]. https://aware.essentialmeds.org/groups. |
| [22] | BURKE J P. Infection control - a problem for patient safety[J].N Engl J Med,2003,348(7):651-656. doi:10.1056/NEJMhpr020557URL |
| [23] | FREEMAN M C, STOCKS M E, CUMMING O, et al. Hygiene and health: systematic review of handwashing practices worldwide and update of health effects[J].Trop Med Int Health,2014,19(8):906-916. doi:10.1111/tmi.12339pmid:24889816 |
| [24] | WOLF J, PRÜSS-USTÜN A, CUMMING O, et al. Asses-sing the impact of drinking water and sanitation on diarrhoeal disease in low- and middle-income settings: systematic review and meta-regression[J].Trop Med Int Health,2014,19(8):928-942. doi:10.1111/tmi.2014.19.issue-8URL |
| [25] | SMITH A M, HUBER V C. The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza[J].Viral Immunol,2018,31(2):159-173. doi:10.1089/vim.2017.0138pmid:29148920 |
| [26] | POOLMAN J T. Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections[J].NPJ Vaccines,2020,5:84. doi:10.1038/s41541-020-00232-0pmid:32963814 |
| [27] | NAKAYA H I, BRUNA-ROMERO O. Is the gut microbiome key to modulating vaccine efficacy?[J].Expert Rev Vaccines,2015,14(6):777-779. doi:10.1586/14760584.2015.1040395pmid:25915555 |
| [28] | Society of Critical Care Medicine (SCCM). Surviving sepsis campaign 2021 adult guidelines[R/OL]. 2021-12-08[2023-04-17]. https://sccm.org/SurvivingSepsisCampaign/Guidelines/Adult-Patients. |
| [29] | SINGER M, DEUTSCHMAN C S, SEYMOUR C W, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J].JAMA,2016,315(8):801-810. doi:10.1001/jama.2016.0287pmid:26903338 |
| [30] | MIETHKE M, PIERONI M, WEBER T, et al. Towards the sustainable discovery and development of new antibio-tics[J].Nat Rev Chem,2021,5(10):726-749. doi:10.1038/s41570-021-00313-1 |
| [31] | LIM C, ASHLEY E A, HAMERS R L, et al. Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries[J].Clin Microbiol Infect,2021,27(10):1391-1399. doi:10.1016/j.cmi.2021.05.037URL |
| [1] | ZHAN Dui, NIMA Zhuoma, DOU Ji, PINGCUO Zhuoma, QI Jinlei.Analysis of all-cause mortality data of residents in Shannan City, Tibet, 2021[J]. Journal of Diagnostics Concepts & Practice, 2023, 22(06): 562-566. |
| [2] | .[J]. Journal of Diagnostics Concepts & Practice, 2010, 9(03): 252-254. |
| [3] | .[J]. Journal of Diagnostics Concepts & Practice, 2003, 2(01): 25-28. |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
